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Introduction
Methylene blue (methylthionine chloride; MB) is a widely accepted pharmacological tool in the analysis of the nitric oxide (NO)-pathway. MB is known to be an inhibitor of soluble guanylate cyclase (Ignarro et al., 1984) , although a few authors consider this eect to be rather weak (Marczin et al., 1992) . Others have shown that MB is a direct inhibitor of NO-synthase and other iron-containing enzymes (Mayer et al., 1993) . MB is known to inhibit directly the vascular smooth muscle relaxation induced by the endothelium-derived relaxing factor (EDRF, NO) itself or by nitrates, which are known to release NO in vitro and in vivo (Martin et al., 1985; McMahon & Kadowitz, 1992) .
We recently used MB as a tool in a clinical pharmacological study, where the vasodilator eects of acetylcholine (ACh) and methacholine (MCh) in the human forearm vascular bed were compared by means of venous occlusion plethysmography . Both ACh and MCh are considered to be non-selective muscarinic receptor agonists, which both activate the various M-receptor subtypes (M 1 ± M 4 ) (Eglen & Whiting, 1990) . The endothelium-dependent vasodilatation caused by both MCh and ACh is triggered by stimulation of endothelial M 3 -receptors and the subsequent release of EDRF/ NO. MCh has proved to be a signi®cantly more potent vasodilator than ACh (Kemme et al., 1995) , and we explained this quantitative dierence by the sensitivity of ACh for degradation by acetylcholinesterases (AChE), which does not aect MCh. When MB was used as a pharmacological tool, our attention was drawn to the ®nding that MB markedly potentiated the vasodilator response to ACh but not that to MCh (Bruning et al., 1994) . MB may be speculated to activate the cholinergic system, possibly by inhibiting AChE and/or other esterases. Furthermore, intoxication with MB in man is known to provoke a series of symptoms (bronchial, gastrointestinal, haemodynamic) which would be in accordance with cholinergic activation (e.g. Martindale 30th edition, 1993). These considerations prompted us to study the possible interaction between MB and certain components of the cholinergic nervous system in vitro.
For this purpose we investigated the in¯uence of MB on two types of cholinesterases and on human serum.
Since the stimulation of muscarinic receptors is often used to provoke the release of EDRF/NO from the endothelium we extended our study to test the possibility of a direct interaction of MB with muscarinic receptors. For this purpose the in¯u-ence of MB on [ 3 H]-N-methylscopolamine binding in rat ventricular homogenate preparations was investigated as well.
Methods

Esterase activity
Esterase activity was quanti®ed by the method of Rappaport et al. (1959) , by use of a commercially available, colorimetric kit (cholinesterase endpoint, Sigma diagnostics). To establish the enzymatic activity we used the serum of 6 healthy male volunteers (mean age 24 years, range 19 ± 31) as well as commercially available, puri®ed human pseudocholinesterase and bovine erythrocyte true acetylcholinesterase. The protocol for the use of human material was approved by the Medical Ethics Committee of the University Hospital and informed consent was obtained from all subjects. The serum 0.2 ml was diluted with 0.2 ml isotonic saline. The puri®ed human pseudocholinesterase and bovine true acetylcholinesterase were dissolved in isotonic saline to a concentration of 8 u 0.4 ml 71 and 2 u 0.4 ml 71 , respectively. One unit pseudocholinesterase is de®ned as the activity that will hydrolyse 2.5 mmol ACh min 71 at 378C at pH 8.0. One unit true acetylcholinesterase is de®ned as the activity that will hydrolyse 1 mmol ACh min 71 at 378C, at pH 8.0. Blanks were prepared by esterase inactivation at 608C for 10 min to compensate for background absorbance induced by the sample. The active and inactivated enzymes were incubated with ACh, m-nitrophenol and various concentrations of MB (0.1 ± 100 mmol l
71
) in a ®nal volume of 5.6 ml at 258C at pH 7.8 for 30 min. The decreasing pH, induced by the formation of acetic acid from the enzymatic hydrolysis of acetylcholine, causes a change of colour of the acidbase indicator m-nitrophenol. This results in an increased absorption of light at a wavelength of 420 nm which is proportional to the amount of acetic acid. The measurements were performed in 1 cm cuvettes with a Zeiss Specord S10 spectrophotometer, with distilled water as reference. The actual results were obtained by subtracting the absorption values of the test tubes from those of the blanks. The calibration was performed by adding increasing amounts of acetic acid to the assay with inactivated esterases and measuring the absorption. The results are expressed as Rappaport units which are de®ned as the amount of cholinesterase which will liberate 1 mmol of acetic acid from ACh in 30 min at 258C, at pH 7.8, under the conditions of this test. A spectrogram of MB (100 mmol l
) and a calibration curve in the presence MB were recorded to rule out any interference with the colorimetric assay. After cervical dislocation, the carotid arteries were opened and the hearts were rapidly excised. The binding experiments were performed according to Doods et al. (1987) . The left ventricles were immersed in ice-cold HEPES buer (20 mmol l 71 HEPES, 100 mmol l 71 NaCl, 10 mmol l 71 MgCl 2 , pH 7.5) and homogenization was performed with a Polytron PT homogenizer. The homogenate was ®ltered through four layers of cloth gauze and centrifuged at 50,0006g for 20 min. The pellet was rehomogenized and diluted to a ®nal membrane concentration of 0.5 ± 1.0 mg ml 71 . The protein content of the ®nal membrane preparation was assessed by using the method of Bradford (1976) . All procedures were carried out at 48C. Samples, (500 ml), of the membrane suspension were incubated at 378C for 20 min with 0.4 nmol l 71
) in a ®nal volume of 1 ml. Non-speci®c binding was de®ned as binding in the presence of 10 mmol l 71 dexetimide. The incubation was terminated by dilution with 3 ml ice-cold HEPES standard assay buer. Separation of bound and free [ 3 H]-NMS was achieved by rapid vacuum ®ltration across Whatman GF/B ®lters (Whatman International Ltd, Maidstone, Kent, U.K.), followed by three washes with 3 ml ice-cold HEPES buer. The radioactivity on the ®lters was measured by standard scintillation counting techniques.
Drugs used
The colorimetric cholinesterase kit (Cholinesterase endpoint No. 420, Sigma Diagnostics), the bovine true cholinesterase (from erythrocytes), the human pseudocholinesterase (from serum) and methylene blue were obtained from Sigma Chemical Co (St Louis, MO, U.S.A.). The radioligand used to analyse muscarinic receptor binding sites was [ 
Statistical evaluation
The results concerning the esterase activity are presented as percentage of the absorbance in the absence of MB at a wavelength of 420 nm. Means+s.e.mean of 4 ± 6 individual experiments, each performed twice, are depicted in Figure 1 . The concentrations which produced a half-maximal inhibition ( actual binding at an inhibitor concentration A, B max is the maximal binding and IC 50 the concentration of the competitor that competes for half of the speci®c binding. The IC 50 value is expressed as mean+s.e.mean of 4 individual experiments, each performed twice. The K i value of MB was calculated according to Cheng and Pruso (1973) .
Results
Cholinesterase activity
After 30 min of incubation at 258C the chosen amounts of serum, true acetylcholinesterase and pseudocholinesterase hydrolysed about 100 to 120 mmol ACh which equals 100 to 120 Rappaport units. The colorimetric measurement of ACh hydrolysis by m-nitrophenol at a wavelength of 420 nm was not disturbed by MB, which shows signi®cant absorption below 350 and above 450 nm. The calibration curve, obtained with increasing concentrations of acetic acid to validate the indicator reaction with m-nitrophenol, was not aected by MB. The measurements of the samples at the endpoint (30 min) showed that MB inhibited the activity of the bovine true acetylcholinesterase, the human pseudoesterase and the human serum in a concentration-dependent manner. The cholinesterase activity in the human serum and the puri®ed human pseudocholinesterase were blocked completely by the highest concentrations of MB, whereas maximal inhibition of the bovine true acetylcholinesterase was found to be 73+3.3%. The half maximal inhibitory concentrations of MB and the steepness of the concentration-inhibition curves are presented in Table 1 . . At high concentrations MB was able to displace the radioligand completely from its speci®c binding site. However, a non-concentration-dependent reduction of the speci®c binding by 13+2% was visible at MB concentrations in the range of 0.1 nmol l 71 to 0.1 mmol l 71 .
Discussion
MB was and is widely used as a highly speci®c inhibitory tool for the analysis of the L-arginine-NO pathway and the endothelium. It can inhibit EDRF/NO-induced vasodilatation by scavenging and inactivating nitric oxide (Marshall et al., 1988; Wolin et al., 1990) . Beside this oxyhaemoglobin-like eect (Doyle & Hoekstra, 1981) MB interacts with the active haeme centre (Martin et al., 1985) and the haeme-de®cient apoenzyme (Tsai et al., 1983) of soluble guanylate cyclase, thereby inhibiting the formation of the relaxant second messenger guanosine-3',5'-cyclic monophosphate (cyclic GMP). So far the inhibitory eect of methylene blue on induced vasodilatation was taken as indicative of an involvement of nitric oxide and/ or the soluble guanylate cyclase (Ignarro et al., 1984) . However, recent investigations have revealed the MB exerts eects other than those aforementioned, like inhibition of the endothelial nitric oxide synthase (Mayer et al., 1993) , inhibition of prostacyclin synthesis (Martin et al., 1989; Okamura et al., 1990) , impairment of noradrenaline uptake, release and metabolism (Soares-Da-Silva & Caramona, 1988) and a possible interaction with G-proteins (Han et al., 1995) .
Classical textbooks on pharmacology and pharmacopoeia mention eects of MB which might suggest an in¯uence on certain elements of the cholinergic nervous system and/or its adjacent receptors (e.g. Martindale 30th edition, 1993). As discussed in the Introduction, we observed a clear potentiation by MB of the vasodilatation induced by acetylcholine in the human forearm vascular bed (Bruning et al., 1994) .
In the present investigation we explored two mechanisms, one stimulating and one inhibitory, by which MB could possibly interact with the cholinergic system. The ®rst was interference with the elimination of acetylcholine and, the second, an interaction with ACh muscarinic receptors.
When exposing dierent types of cholinesterases to MB, we indeed observed a signi®cant inhibitory eect on the cholinesterase activity of human serum, as well as on puri®ed bovine true acetylcholinesterase and human pseudocholinesterase. The esterase inhibition proved to be concentrationdependent in all three preparations studied. The MB concentrations required to bring about a signi®cant degree of esterase activity inhibition are within the range of those frequently applied for the analysis of the L-arginine-NO-pathway, where MB is commonly used in concentrations of 10 75 mol l 71 or higher (Martin et al., 1985) . In other words, MB may be considered as a cholinesterase inhibitor at the concentrations at which it is used for the investigation of the L-arginine-NOpathway.
This ®nding also explains the potentiation of the vasodilator eects of ACh by MB in the human forearm vascular bed, established in clinical pharmacological studies (Bruning et al., 1994) . Furthermore, it seems likely that the symptoms of cholinergic activation associated with MB poisoning are caused by inhibition of cholinesterase activity. It might even contribute to the ileal/jejunal stenosis seen in the newborn after intra-amniotic injection of MB, an adverse eect of MB still with an unknown mechanism of action (Nicolini & Monni, 1990; Dolk, 1991) .
Muscarinic receptor stimulation by means of appropriate agonists, such as acetylcholine or methacholine, is a generally accepted procedure to investigate the functional role of the endothelium in blood vessels, where endothelial M 3 -receptors are known to mediate the release of EDRF/ nitric oxide, both in vivo (McMahon & Kadowitz, 1992) and in vitro (Martin et al., 1985) . For this reason it seemed of interest to know whether MB may display anity for muscarinic receptors. Our displacement experiments with [
3 H]-NMS indeed indicate that MB possesses substantial anity for muscarinic receptors, with a K i value of 5.8610 77 mol l 71 , which corresponds to or is even lower than that used for the analysis of the L-arginine-NO-pathway (Martin et al., 1985) . This muscarinic receptor antagonism has also been demonstrated recently in electrophysiological experiments (Gerges et al., 1997) .
In the present study, MB was shown to display opposing eects on the cholinergic system: an activating eect by inhi- bition of the elimination of ACh, versus an inhibitory eect by the occupation of muscarinic receptors. It might be speculated that in those systems where the elimination of ACh by esterases eectively determines the concentration of the transmitter in the biophase, as in various in vivo conditions, MB exerts ACh potentiating properties. If a competitive type of antagonism is assumed the increasing concentrations of ACh under those conditions will displace MB from the muscarinic receptors. On the other hand, if the elimination of ACh does not play a decisive role, in particular under in vitro conditions, MB might eectively compete with the transmitter for its binding site, which would be manifest as mere ACh antagonism.
In conclusion, MB may be considered as a cholinesterase inhibitor with additional, relevant anity for muscarinic binding sites at the concentrations in which it is used for investigations into the endothelial system. In our opinion these interactions between MB and the cholinergic system invalidate the use of MB as a tool for investigation of the L-arginine-NOpathway, in particular when muscarinic receptor stimulation is involved.
